What are the manufacturers of trifluridine and tipiracil (Lanceford)?

Trifluridine and tipiracil (Lonsurf), a drug that plays an important role in the treatment of colorectal cancer and gastric or gastroesophageal junction adenocarcinoma, was developed and produced by the well-known Taiho Pharmaceutical Co. (Taiho Oncology Co., Ltd.). The drug is a rising star in cancer treatment thanks to its unique two-ingredient combination, trifluridine and tipiracil.

The therapeutic mechanism of trifluridine and tipiracil is quite subtle. When cancer cells take up these two components, trifluridine will be cleverly integrated into the DNA of the cancer cells, thereby interfering with their synthesis process and inhibiting cell proliferation. Tipiracil inhibits the metabolism of trifluridine to increase its exposure in the body, thereby enhancing the therapeutic effect.

Trifluridine and tipiracil are approved to treat adult patients with certain types of cancer. These patients include those with metastatic colorectal cancer who have undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens, as well as patients with metastatic gastric or gastroesophageal junction adenocarcinoma who have received multiple chemotherapy and HER2/neu-targeted therapies. Instructions for use in tablet form advise patients to take the drug by mouth at specified times and doses with food during each 28-day treatment cycle.

However, as with all medications, the use of trifluridine and tipiracil comes with some potential side effects and risks. Common adverse reactions include hematological abnormalities such as neutropenia, anemia, and thrombocytopenia, as well as non-hematological toxicities such as fatigue, nausea, and decreased appetite. Therefore, patients must strictly follow their doctor's instructions and monitoring when using this drug.

In summary, trifluridine tipiracil (Longsiphor), as an outstanding research and development achievement of Taiho Pharmaceutical Co., provides a new treatment option for patients with colorectal cancer and adenocarcinoma of the stomach or gastroesophageal junction. However, when using this drug, both patients and physicians need to fully understand its treatment mechanisms, indications, and potential risks to ensure a safe and effective fight against cancer.